TABLE 3.
Comparison of Patients with Low Versus High Tumoral Uptake on TSPO PET
| Characteristic | SUVmax < 2.2, n = 23 | SUVmax ≥ 2.2, n = 22 | Significance* |
|---|---|---|---|
| Age (y) | 62.6 (51.2–80.4) | 63.9 (30.6–84.2) | P = 0.910 |
| Sex | P = 0.270 | ||
| Male | 12 (52.2%) | 15 (68.2%) | |
| Female | 11 (47.8%) | 7 (31.8%) | |
| MGMT promoter methylation status | P = 0.563 | ||
| Methylated | 7 (30.4%) | 5 (22.7%) | |
| Unmethylated | 16 (69.6%) | 17 (77.3%) | |
| TERT promoter mutation status | P = 0.954 | ||
| Mutant | 20 (86.9%) | 19 (86.4%) | |
| C250T mutation | 9 (39.1%) | 6 (27.3%) | |
| C228T mutation | 11 (47.8%) | 13 (59.1%) | |
| Wild-type | 3 (13.0%) | 3 (13.6%) | |
| KPS | 80% (60–100%) | 80% (60–90%) | P = 0.161 |
| Mode of surgery | P = 0.528 | ||
| Stereotactic biopsy | 17 (73.9%) | 18 (81.8%) | |
| Microsurgical resection | 6 (26.1%) | 4 (18.2%) | |
| Mode of radiotherapy | P = 0.185 | ||
| Conventional | 14 (60.9%) | 9 (40.9%) | |
| Hypofractionated | 9 (39.1%) | 13 (59.1%) | |
| Concomitant temozolomide | P = 0.266 | ||
| Yes | 19 (82.6%) | 15 (68.2%) | |
| No | 4 (17.4%) | 7 (31.8%) | |
| Contrast enhancement | P = 0.022 | ||
| Yes | 18 (78.3%) | 22 (100.0%) | |
| No | 5 (21.7%) | 0 (0.0%) | |
| CE-T1w MRI volume (mL) | 10.2 (0.0–112.6) | 14.5 (0.4–78.6) | P = 0.188 |
| T2w MRI volume (mL) | 35.2 (0.0–272.0) | 56.2 (0.4–168.5) | P = 0.188 |
*
Bold font highlights the statistically significant associations.
MGMT = O6-alkylguanine DNA methyltransferase gene; TERT = telomerase reverse transcriptase gene; KPS = Karnofsky performance status scale; CE-T1w = contrast-enhanced T1-weighted; T2w = T2-weighted.
Qualitative data are number and percentage; continuous data are median and range.